相关实验视频

Updated: May 23, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在胰腺癌中,NLRP4驱动了olaparib耐药性

Mingming Xiao^1,2,3,4,5, Xianjun Yu^1,2,3,4,5, Si Shi^1,2,3,4,5

¹Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Autophagy reports

|May 21, 2025

概括

通过增强DNA修复和自,NLRP4上调增加了胰腺癌中对olaparib的耐药性. 抑制NLRP4,ROS或自可以提高olaparib治疗的有效性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

奥拉巴里布已被批准用于转移性胰腺癌与BRCA突变.
对olaparib的耐药性是胰腺癌的重大临床挑战.
了解耐药机制是开发改进的向疗法的关键.

研究的目的:

为了研究NLRP4 (NLR家族pyrin域含有4) 在胰腺癌中olaparib耐药性的作用.
阐明NLRP4影响治疗反应的分子机制.
确定潜在的治疗策略来克服olaparib耐药性.

主要方法:

评估NLRP4表达与olaparib耐药性相关.
研究NLRP4参与DNA损伤反应 (DDR) 和自.
研究了抑制NLRP4,线粒体ROS或自的对癌细胞对olaparib敏感性的影响.

主要成果:

NLRP4的上调与对olaparib的抗性增加有关.
在olaparib治疗后,NLRP4增强了DNA修复能力,并促进了ROS的产生和自.
抑制线粒体ROS (MitoQ) 或自 (chloroquine) 会使胰腺癌细胞对olaparib敏感.

结论:

NLRP4促进了自和DNA修复,从而促进了olaparib耐药性.
准NLRP4,线粒体ROS或自可能是提高olaparib疗效的有效策略.
低NLRP4表达可能预测对olaparib治疗的良好反应.

关键词:

对DNA损伤的反应反应在NLRP4中,NLRP4是NLRP4的类型.这就是Olaparib.这就是ROSOS ROS.自自是自的过程.

更多相关视频

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...